Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1105070.RATtrR8dbX7A3LN7lQDziiLqBqLGVXNBKQIKWjVrChr0k130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1105070.RATtrR8dbX7A3LN7lQDziiLqBqLGVXNBKQIKWjVrChr0k130_assertion type Assertion NP1105070.RATtrR8dbX7A3LN7lQDziiLqBqLGVXNBKQIKWjVrChr0k130_head.
- NP1105070.RATtrR8dbX7A3LN7lQDziiLqBqLGVXNBKQIKWjVrChr0k130_assertion description "[They have represented a paradigm of molecular-targeted therapies for solid tumors since the discovery of KIT mutations and KIT expression in GIST in 1998, which opened the way to the use of imatinib, a tyrosine kinase inhibitor able to inhibit the growth of cells expressing KIT-mutant isoforms.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1105070.RATtrR8dbX7A3LN7lQDziiLqBqLGVXNBKQIKWjVrChr0k130_provenance.
- NP1105070.RATtrR8dbX7A3LN7lQDziiLqBqLGVXNBKQIKWjVrChr0k130_assertion evidence source_evidence_literature NP1105070.RATtrR8dbX7A3LN7lQDziiLqBqLGVXNBKQIKWjVrChr0k130_provenance.
- NP1105070.RATtrR8dbX7A3LN7lQDziiLqBqLGVXNBKQIKWjVrChr0k130_assertion SIO_000772 23975171 NP1105070.RATtrR8dbX7A3LN7lQDziiLqBqLGVXNBKQIKWjVrChr0k130_provenance.
- NP1105070.RATtrR8dbX7A3LN7lQDziiLqBqLGVXNBKQIKWjVrChr0k130_assertion wasDerivedFrom befree-2016 NP1105070.RATtrR8dbX7A3LN7lQDziiLqBqLGVXNBKQIKWjVrChr0k130_provenance.
- NP1105070.RATtrR8dbX7A3LN7lQDziiLqBqLGVXNBKQIKWjVrChr0k130_assertion wasGeneratedBy ECO_0000203 NP1105070.RATtrR8dbX7A3LN7lQDziiLqBqLGVXNBKQIKWjVrChr0k130_provenance.